Furazolidone and nitrofurantoin, oral nitrofuran derivatives with broad-spectrum antimicrobial properties already in clinical use, were compared for activity against Pneumocystis carinii in an immunosuppressed rat model of P. carinii pneumonia. Furazolidone exhibited only slight activity as a prophylactic agent but was moderately effective in the therapy of pneumocystosis. The median histologic score and organism count fell from 4+ and and their toxic effects on the rats will probably discourage investigation of this drug in the treatment of pneumocystosis in humans. Nevertheless, since many nitrofurans have been synthesized, further exploration of this class of compounds might be helpful in developing new anti-P. carinii agents or in studying structureactivity relationships.
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Pneumocystis carinii is a leading cause of pneumonia in immunosuppressed patients. The incidence of pneumocystosis has increased markedly over the past decade in association with the emergence of AIDS (34) . Treatment of P. carinii pneumonia in AIDS patients has been hindered by a high frequency of recurrence and of toxic reactions to antimicrobial drugs. Anti-P. carinii compounds currently in clinical use include inhibitors of dihydrofolate reductase (e.g., trimethoprim [TMP] , trimetrexate), sulfonamides (sulfamethoxazole [SMX] ), and sulfones (dapsone); diamidines (pentamidine isethionate); polyamine inhibitors (adifluromethylornithine); and the combination of clindamycin and primaquine (2, 11, 13, 21, 27) .
Our laboratory has been engaged in developing new forms of P. carinii therapy for the past several years (8, 15, 35, 36) . Drug selection has been hampered by the lack of knowledge about the metabolic pathways of the organism. Studies are conducted in an animal model in which rats given corticosteroids spontaneously develop pneumocystosis by a process of reactivation of latent infection. Although this system permits evaluation of relatively few compounds, it has been a reliable predictor of drug activity in humans (10, 12) .
Here we report our experience with two nitrofuran derivatives, furazolidone and nitrofurantoin. Nitrofurans possess broad antimicrobial properties, including activity against trypanosomes (4, 20, 25, 26, 29, 31) . Our rationale for testing them against P. carinii was based on the following considerations. First, several classes of drugs (e.g., diamidines, polyamine inhibitors, purine nucleosides) with antitrypanosomal properties have been shown to be effective against P. carinii, although the specific mechanisms of action are unknown (8, 21, 28, 36) . Second, since furazolidone and nitrofurantoin are oral preparations and are already in clinical use, they would be much easier to develop as anti-P. carinii drugs than would unlicensed compounds with poorly * Corresponding author. understood pharmacokinetic properties or toxicological profiles.
MATERIALS AND METHODS
Experimental design. (i) Treatment. The animal protocol that we used has been described in detail previously (15, (35) (36) (37) . In brief, adult male Sprague-Dawley rats (Harlan Industries, Madison, Wis.), each weighing about 250 g, were housed in a conventional colony and placed on an immunosuppressive regimen of 4 mg of methylprednisolone (Depot Medrol; The Upjohn Co., Kalamazoo, Mich.) injected subcutaneously once a week, a low (8%)-protein diet (Bioserv, Frenchtown, N.J.), and 1 mg of tetracycline powder (American Cyanamid, Wayne, N.J.) per ml in the drinking water to induce P. carinii pneumonia. The animals were weighed periodically, and a few rats were sacrificed to monitor the development of the disease. At 5 to 6.5 weeks, when pneumocystosis had reached moderate intensity, the rats were randomly divided into treatment and control groups of about 15 to 20 animals each. Antimicrobial drugs to be tested were administered for 3 weeks, during which time all rats remained on the immunosuppressive regimen. Some control rats received a placebo, whereas others received no therapy; no differences in the extent of pneumocystosis were noted in these animals. At the end of the period of therapy, the animals were sacrificed by an overdose of halothane anesthesia and the lungs were processed for analysis.
(ii) Prophylaxis. In the prophylaxis studies, the drugs were evaluated for their ability to prevent the development of P. carinii pneumonia. They were administered throughout the entire 7 (Macrodantin; Norwich Eaton) were purchased commercially. The furazolidone and nitrofurantoin treatment and prophylaxis regimens are summarized in Table 1 . The liquid suspensions of these drugs were administered in the standard concentration as specified by the manufacturer. The tablets were ground into a powder and mixed with water in an attempt to deliver a larger dose of these drugs in a smaller volume. The nitrofurantoin macrocrystal capsules were emptied, and the contents were mixed with water into a suspension. TMP-SMX was a gift from Edmund Wise, Burroughs-Wellcome, Research Triangle Park, N.C. All drugs were administered on a milligram-per-kilogram basis in single doses or two divided doses by oral gavage. Dosing was based on the average weight of the rats (usually about 150 g) at the beginning of therapy and did not change over the 3-week course of drug administration.
Evaluation of drug efficacy. As in our earlier studies (15, 35, 36) , drug effectiveness was based on histologic and quantitative analysis of the severity of pneumocystosis rather than on survival because some rats died from causes unrelated to P. carinii (e.g., other opportunistic infections, adverse drug reaction) before completing a full course of therapy. Unless otherwise specified, only animals which received at least 10 days of treatment were included in the data analysis, since we have found that it usually takes this long to observe a therapeutic effect. P. carinii pneumonia in drug-treated animals was compared with that in the controls in the same experiment. Our previous studies revealed little variation in the extent of pneumocystosis in the control rats in different experiments; the results of several experiments involving different dose regimens of a drug were therefore sometimes combined to facilitate data presentation and interpretation (35, 36) . Such a procedure was also followed in the present report.
To evaluate P. carinii infection, the left lung of each rat was removed, fixed and inflated with 4% formaldehyde, cut into three horizontal sections, stained with hematoxylin and eosin and Grocott's methenamine silver, coded, and read in a blinded manner (15) . The extent of the pneumonia was graded on a semiquantitative scoring system ranging from 0+ (negative) to 4+ (very severe; >75% of alveoli involved). The right lung was weighed, homogenized in a stomacher (Tekmar, Inc., Cincinnati, Ohio), stained with cresyl echt violet for quantitation of P. carinii cysts and (in selected instances) with Diff-Quik (American Scientific Products, McGaw Park, Ill.) for quantitation of the nuclei of all stages of the organism (7, 8, 15 (Fig. 1) . These results were statistically significant (P < 0.001) by the Wilcoxon rank sum test, using both methods of assessment. The therapeutic efficacy of furazolidone could not be consistently related to dose, preparation, or duration of administration. No significant differences were found in the histologic scores or cyst counts of groups F-1, F-3, F-4, and F-5 (Table 1) by the Kruskal-Wallis test. The best results were achieved with furazolidone in a dose of 100 mg/kg/day as a liquid suspension (group F-2), but administration of the same dose regimen in a separate experiment (group F-3) was somewhat less successful. Rats administered furazolidone at 200 mg/kg/day in powdered form (group F-5) had a markedly shortened survival (median duration, 9.5 days [ Fig. 2 ). These results were significantly better than those for the control steroid group (P < 0.001) and the furazolidone treatment groups (P < 0.001) and approached the values of the control normal (C/N) rats which received no immunosuppression.
Furazolidone prophylaxis. Furazolidone in a dose of 50 mg/kg/day as a liquid suspension (group F-6) and TMP-SMX in a dose of 0.6 mg of TMP per kg per day plus 3 mg of SMX per kg per day were compared as prophylactic agents (Table  2 ; Fig. 2) . Rats on the F-6 regimen had a median histologic score of 3+ and P. carinii cyst count of 2.2 x 108 per lung compared with corresponding values of 4+ and 4.1 x 108 per lung in the control steroid (C/S) group; although the cyst count data achieved statistical significance (P < 0.01), the biological significance of this finding is questionable. By contrast, the TMP-SMX regimen lowered the median histologic score to 0+ and the cyst count to 1.1 x 106 per lung. 
DISCUSSION
This study has cornpared furazolidone and nitrofurantoin in the therapy of experimental pneumocystosis. Furazolidone exhibited moderate anti-P. carinii activity, causing a fall in the histologic score from 4+ to 1+ to 2+ and usually a >10-fold decline in cyst counts. Although this efficacy was lower than that obtained with TMP-SMX, it was comparable to our results with pentamidine in earlier studies (36) . We are aware of only one report of the use of furazolidone in the rat model of P. carinii pneumonia (40) , but it is difficult to draw any firm conclusions on the basis of the limited available data.
Furazolidone has broad-spectrum activity against bacteria and Giardia lamblia, and its major clinical use in humans has been in the therapy of bacterial diarrhea and giardiasis (6, 9, 19, 23, 26, 33) . The drug has also exhibited activity in vitro or in animal models against leishmanias, trichomonads, trypanosomes, and filariae, but clinical trials have been disappointing (1, 3-5, 14, 16, 18, 22, 24, 38) . The doses of furazolidone in the present study are much higher than the usual 5-to 9-mg/kg/day dose used in humans (19, 31) . The efficacy of furazolidone in the treatment of pneumocystosis was not enhanced by altering the dose or the oral preparation of the drug. Although the reasons for the lack of a doseresponse curve are unclear, we have encountered this situation with other drugs tested in the rat model. TMP-SMX, for example, remains highly active against P. carinii over a broad range of doses (33a, 35).
The antimicrobial properties of furazolidone and other nitrofuran compounds are related to the 5-nitro group on the furan ring, whereas the chemical characteristics, toxicity, and clinical use are due mainly to the side chain at the 2-position (4, 20, 25, 29, 31 (39) . Whether the active form of furazolidone against P. carinii is the parent compound or some metabolite is unknown. Furazolidone is actively metabolized probably both in the intestine and in the liver; nitro reduction to the aminofuran is the major route, but other pathways may also exist (30, 32, 39) .
In contrast to its success in the therapy of pneumocystosis, furazolidone was less effective in the prevention of the disease. This was due, at least in part, to the poor tolerance of the rats to chronic administration of the drug. Furazolidone toxicity was related to the dose and duration of administration, but it is also possible that other factors (e.g., components of the immunosuppressive regimen, other opportunistic pathogens) contributed to some of the adverse reactions experienced by the animals.
The present study has shown that nitrofurantoin has little activity in the treatment of experimental pneumocystosis. As with furazolidone, no improvement occurred with different formulations of the drug. Nitrofurantoin has broad antibacterial properties and is well absorbed from the gastrointestinal tract; however, it achieves low levels in serum and so its clinical use has been limited to the treatment of urinary tract infections (17, 31) . The differences in anti-P. carinii activity between furazolidone and nitrofurantoin could reflect differences in chemical structure or be due to factors such as pharmacokinetics. Evidence supporting the former comes from studies which have shown that nitrofurtimox, a nitrofuran compound used in the treatment of Chagas' disease, is ineffective against P. carinii in the rat model (13, 33a) .
Although furazolidone is licensed for clinical use, the high doses used in this study and the side effects experienced by the rats emphasize the need for caution and further testing before any human studies are contemplated. Nevertheless, the data obtained here have important potential implications for P. carinii drug development. These drugs are nitrofurans and hence represent a class of compounds which are unrelated to currently available anti-P. carinii agents. At least 3,500 nitrofuran derivatives have been synthesized, but only a select few have been developed for clinical use (4) . Perhaps investigation of some of these compounds would lead to the development of new analogs with improved efficacy and less toxicity. These drugs would also be helpful in studying structure-activity relationships and mechanisms of action against P. carinii if better in vitro systems for working with this organism were available.
